Safety and Immunogenicity of a Candidate MERS-CoV Vaccine (MERS001)

MERS (Middle East Respiratory Syndrome) Clinical Trial

Official title: A Phase I Study to Determine the Safety and Immunogenicity of the Candidate Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Vaccine ChAdOx1 MERS in UK Healthy Adult Volunteers

Status Terminated

Clinical Trial Summary

This is a clinical trial in which healthy volunteers will be administered an experimental MERS vaccine. The vaccine ChAdOx1 MERS will be administered alone both as a single administration and with a homologous prime-booster.

Clinical Trial Description

All vaccinations will be administered intramuscularly. In Groups 1-3, each volunteer will receive one vaccination in total. In Groups 4 and 5, each volunteer will receive two vaccinations in total. There are five different vaccine schedules: Group 1 (n=6) will receive 5 x 10^9 vp ChAdOx1 MERS . Group 2 (n=9) will receive 2.5 x 10^10 vp ChAdOx1 MERS. Group 3 (n=9) will receive 5 x 10^10 vp ChAdOx1 MERS. Group 4 (n=6-12) will receive 2.5 x 10^10 vp ChAdOx1 MERS at week 0 followed by a boost of 2.5 x 10^10 vp ChAdOx1 MERS at week 26. Group 5 (n=6-12) will receive 2.5 x 10^10 vp ChAdOx1 MERS at week 0 followed by a boost of 2.5 x 10^10 vp ChAdOx1 MERS at week 4. The study will assess the safety of the vaccines, and the immune responses to the vaccinations. Immune responses are measured by tests on blood samples. Healthy adult volunteers will be recruited in Oxford, England. ;

Related Conditions & MeSH terms

• Coronavirus Infections
• MERS (Middle East Respiratory Syndrome)
• Syndrome

• NCT number: NCT03399578
• Study type: Interventional
• Source: University of Oxford
• Status: Terminated
• Phase: Phase 1
• Start date: March 14, 2018
• Completion date: September 17, 2021